Product Description
Progesterone Receptor (phospho Ser294) Antibody [608] | XPS-1024 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Progesterone receptor (Ser294) monoclonal antibody was raised against a synthetic phosphopeptide corresponding to amino acids residues surrounding the phosphoSer294of human progesterone receptor.
Research Area: Signal Transduction, Growth Factors, Phospho-Specific
Tested Application: WB, IHC
Application: As shown in Clemm, et al. (2000) , cited above, the antibody specifically reacts with the progesterone receptor phosphorylated at Ser294 in T47D cells. Applications include Immunoblotting (IB) , Immunohistochemistry (IHC) and Western Blots (WB) . Initial recommended range of dilutions: 1:1000 to 1:2000. When internally tested under ideal conditions the working dilutions were 1:1000 for IB, IHC and WB.
Specificiy: Progesterone Receptor antibody is specific for the human progesterone receptor phosphorylated at Ser294.
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 90/120
Validation: N/A
Isoform: N/A
Purification: Protein G purified
Clonality: Monoclonal
Clone: 608
Isotype: IgG1
Conjugate: Unconjugated
Physical State: Liquid
Buffer: N/A
Concentration: N/A
Storage Condition: For long term storage –80˚C is recommended, but shorter term storage at –20˚C is also acceptable as aliquots may be taken without freeze/thawing due to the presence of 50% glycerol. Stable for one year.
Alternate Name: N/A
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer. The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (A and B forms) . In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones. Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor. Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser190 and Ser294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor.